The quest for multi-functional medicines: path for progress: the SERM story

Published on July 25, 2011 Reviewed on January 17, 2018   31 min

Other Talks in the Category: Pharmaceutical Sciences

0:00
In the last lecture, we talked about tamoxifen, and the fact that tamoxifen was a failed contraceptive that became the gold standard for the treatment and prevention of breast cancer. Here we're now going to consider the evolution of the use of non-steroidal antioestrogens into being Selective Estrogen Receptor Modulators. In lecture two, we're considering the SERM story, Selective Estrogen Receptor Modulators.
0:31
A chemoprevention is not a new concept. It was Professor Antoine Lacassagne, who back in 1936 made this statement at the American Association for Cancer Research: "If one accepts the consideration of adenocarcinoma of the breast as a consequence of a special hereditary sensibility to the proliferative actions of oestrone" (In those days, oestradiol was not known to be the main sex steroid and activity), "one is led to imagine a therapeutic preventative for subjects predisposed by their heredity to this cancer." Lacassagne was talking about animal models, oophorectomy, preventing breast cancer, but a therapeutic preventative became a potential possibility with the extensive use of tamoxifen in the clinical community and preclinical information that set the scene to move forward into clinical testing.
Hide

The quest for multi-functional medicines: path for progress: the SERM story

Embed in course/own notes